257 results on '"Ehmer, Ursula"'
Search Results
2. Transjugular intrahepatic portosystemic shunt creation (TIPS) in the angio-CT—a hybrid intervention with image fusion
3. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
4. Regional transplant rates depend more on physician-dependent variables than on proximity to transplant center
5. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
6. (Seltene) infektiöse Hepatitiden als wichtige Differenzialdiagnose der unklaren Hepatopathie
7. Secondary sclerosing cholangitis after COVID-19 pneumonia: a report of two cases and review of the literature
8. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
9. PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
10. Isavuconazole and Liposomal Amphotericin B as Successful Combination Therapy of Refractory Invasive Candidiasis in a Liver Transplant Recipient: A Case Report and Literature Review
11. PARP-1 selectively impairsKRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma
12. THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter registry
13. SAT-166 Functional relevance of CD44 for hepatocyte proliferation in diet-induced liver injury models
14. Organhandel mit Nieren
15. Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
16. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
17. Community-driven development of a modified progression-free survival ratio for precision oncology
18. Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation In Vivo
19. Human hepatic organoids for the analysis of human genetic diseases
20. Frequent Follow-Up of Delisted Liver Transplant Candidates Is Necessary: An Observational Study about Characteristics and Outcomes of Delisted Liver Transplant Candidates
21. Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based study
22. Comparison of histological tumour response in patients with hepatocellular carcinoma after transarterial chemoembolization, stereotactic body radiation, or combined therapy
23. CD44 reduces fibrosis development in chronic cholestatic liver injury in Mdr2 knock-out mice
24. Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study
25. Inhibition of SARS-CoV-2 infection by vaccine-induced antibodies and small-interfering RNAs
26. Frequent Follow-Up of Delisted Liver Transplant Candidates Is Necessary: An Observational Study about Characteristics and Outcomes of Delisted Liver Transplant Candidates
27. Promotion of growth factor signaling as a critical function of β-catenin during HCC progression
28. When the pathologist is not too late (for once) – rare infectious causes of acute hepatic dysfunction with distinct histopathological features.
29. Usefulness of 1,3 Beta-d-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii Pneumonia
30. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
31. (Seltene) infektiöse Hepatitiden als wichtige Differenzialdiagnose der unklaren Hepatopathie
32. Intestinal myofibroblasts regulate intestinal epithelial cell plasticity via YAP/TAZ
33. An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes
34. Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature.
35. Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS
36. A targeted screen identifies Dmbt1 as an oncogene in cholangiocarcinoma
37. The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis
38. Expression of human endogenous retrovirus type K HML2 in hepatitis C patients treated with direct acting antiviral therapy
39. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
40. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial
41. Expression of human endogenous retrovirus type K HML2 in hepatitis C patients treated with direct acting antiviral therapy
42. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer
43. IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.
44. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
45. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
46. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma : The DEMAND trial protocol
47. OS-079-YI Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab
48. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.
49. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
50. Relevance of MEK/ERK signaling in biliary differentiation in murine liver cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.